{
    "clinical_study": {
        "@rank": "45359", 
        "arm_group": {
            "arm_group_label": "Eribulin", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive the experimental agent eribulin.  The dose will increase with subsequent cohorts of patients."
        }, 
        "brief_summary": {
            "textblock": "This is a study for children with cancer with no curative treatment options.  The\n      investigators will be giving eribulin, a new chemotherapy agent, for the first time to\n      children.  This study is designed to determine a safe dose the investigators can give to\n      children in larger studies.  The investigators will be monitoring the children on this study\n      for the safety of the treatment and levels of eribulin in the blood after treatment.  The\n      investigators will also study the effect of the agent on the cancer."
        }, 
        "brief_title": "Study of Eribulin in Children With Cancer to Determine Safety", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pediatric Cancer", 
            "Solid Tumors", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "This is a phase I study of eribulin, a novel tubulin inhibitor in children with relapsed and\n      refractory solid tumors including lymphoma.  Dose escalation will be performed in a classic\n      3+3 design starting with 75% of the adult maximum tolerated dose (MTD).  Pharmacokinetics\n      will be done on each patient.  Primary endpoint will be the pediatric MTD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: \u2264 21 years of age at the time of study enrollment\n\n          -  Diagnosis: refractory   or   recurrent   solid   tumors,   including lymphomas,\n             except those with CNS tumors or known CNS metastases\n\n          -  Disease Status: measurable or evaluable disease\n\n          -  Adequate organ function as defined in protocol\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082626", 
            "org_study_id": "Eribulin JEC"
        }, 
        "intervention": {
            "arm_group_label": "Eribulin", 
            "intervention_name": "Eribulin mesylate", 
            "intervention_type": "Drug", 
            "other_name": "Halaven"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase I", 
            "Pediatric", 
            "Cancer", 
            "Lymphoma", 
            "Eribulin"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "rene-mcnall@ouhsc.edu", 
                "last_name": "Rene Y McNall-Knapp, MD", 
                "phone": "405-271-4412"
            }, 
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "73104"
                }, 
                "name": "Jimmy Everest Center for Cancer and Blood Disorders in Children"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors", 
        "overall_contact": {
            "email": "rene-mcnall@ouhsc.edu", 
            "last_name": "Rene Y McNall-Knapp, MD", 
            "phone": "405-271-4412"
        }, 
        "overall_contact_backup": {
            "email": "william-meyer@ouhsc.edu", 
            "last_name": "William H Meyer, MD", 
            "phone": "405-271-4412"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Oklahoma", 
                "last_name": "Rene Y McNall-Knapp, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Oklahoma", 
                "last_name": "Amanda Linz, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The dose that does not cause dose limiting toxicity during the first cycle in more than 1 of 6 subjects", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "13 blood samples will be drawn from each subject over first 8 days of protocol to measure serum levels of the agent eribulin.", 
                "measure": "Pharmacokinetics of eribulin in children with cancer", 
                "safety_issue": "No", 
                "time_frame": "8 days after first dose"
            }, 
            {
                "description": "Archival tumor samples from each subject will be stained for expression of BRCP and ABCB1, transporter proteins responsible for some resistance to chemotherapy.  Will compare expression and response data", 
                "measure": "Tumor expression of BRCP and ABCB1", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Subjects receiving eribulin will have scans approximately every 6 weeks to assess whether the tumors are growing, shrinking, or remaining stable.", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of Oklahoma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oklahoma", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}